HTG Introduces HTG EdgeSeq Reveal RUO Oncology Applications
- HTG EdgeSeq Reveal Immune Signature
- HTG EdgeSeq Reveal Stroma Signature
- HTG EdgeSeq Reveal Tumor Microenvironment Signature
“Our purpose-built signatures are intended to leverage the gene expression data from our PIP assay and enable researchers to better understand the tumor microenvironment including tumor inflammation (Hot vs. Cold) and stromal response to a tumor,” said
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the capabilities and benefits of HTG EdgeSeq Reveal 3.0, including its RUO oncology applications, as well as our plans for the commercialization of additional applications in Oncology and Immunology. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including but not limited to, the risk that HTG EdgeSeq Reveal 3.0, our HTG EdgeSeq RUO assays and related RUO applications may not provide the expected benefits or capabilities; the risk the we may not be successful in our efforts to commercialize additional applications; risks associated with our ability to successfully commercialize our products; the risk that our products and services may not be adopted by biopharmaceutical companies or other customers as anticipated, or at all; and our ability to manufacture our products to meet demand. These and other factors are described in greater detail in our filings with the
Phone: (617) 430-7577
Source: HTG Molecular Diagnostics, Inc.